EUVIMEDEUVIMED entdecken
Crossref

Harnessing marine natural products to inhibit PAD4 triple mutant: A structure-based virtual screening approach for rheumatoid arthritis therapy

Santhiya Panchalingam, Manikandan Jayaraman, Jeyakanthan Jeyaraman, Govindaraju Kasivelu

Archives of Biochemistry and Biophysics · 2024

DOI: 10.1016/j.abb.2024.110164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2024. Verfasst von Santhiya Panchalingam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Ocean Research, Sathyabama Institute of Science and Technology (Deemed to be University), Chennai, 600 119, Tamil Nadu, India. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Biological Products, Protein-Arginine Deiminase Type 4. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Biomolecular Interaction Centre, University of Canterbury.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peptidylarginine deiminase type4 (PAD4) is a pivotal pro-inflammatory protein within the human immune system, intricately involved in both inflammatory processes and immune responses. Its role extends to the generation of diverse immune cell types, including T cells, B cells, natural killer cells, and dendritic cells. PAD4 has recently garnered attention due to its association with a spectrum of inflammatory and autoimmune disorders, notably rheumatoid arthritis (RA). Mutations in the PAD4 gene, leading to the conversion of arginine to citrulline, have emerged as significant factors in the pathogenesis of RA and related conditions. As a calcium-dependent enzyme, PAD4 is central to the citrullination process, a crucial post-translational modification implicated in disease pathophysiology. Its critical role in autoimmune disorders and inflammation makes PAD4 a prime candidate for therapeutic intervention in RA. Inhibiting PAD4 presents a promising avenue for mitigating inflammatory responses and curtailing joint degradation and impairment. To explore its therapeutic potential, a structure-based virtual screening (SBVS) approach was employed, harnessing an array of marine natural products (MNPs) sourced from databases such as CMNPD, MNPD, and Seaweed. Notably, MNPD10752, CMNPD12680, and CMNPD2751 emerged as potential hit molecules, exhibiting adherence to essential pharmacokinetic properties and favorable toxicity profiles. Quantum mechanics studies using density functional theory (DFT) calculations revealed the inhibitory potential of these identified natural products. Further structural elucidation through molecular dynamics simulations (MDS) and principal component-based free energy landscape (FEL) analysis shed light on the stability of MNP-bound PAD4 complexes. In conclusion, this computational study serves as a stepping stone for further experimental evaluation, aiming to explore the potential of MNPs in addressing PAD4-related human pathologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidBiological ProductsProtein-Arginine Deiminase Type 4HumansMutationMolecular Docking SimulationMolecular Dynamics SimulationEnzyme Inhibitors

Stichwörter der Autor:innen

Free energy landscapeMarine natural productsMolecular dynamics simulationPAD4Rheumatoid arthritisVirtual screening

Substanzen

Biological ProductsProtein-Arginine Deiminase Type 4PADI4 protein, humanEnzyme Inhibitors

Autor:innen und Institutionen

  • Centre for Ocean Research, Sathyabama Institute of Science and Technology (Deemed to be University), Chennai, 600 119, Tamil Nadu, India.
  • Structural Biology and Biocomputing Lab, Department of Bioinformatics, Alagappa University, Karaikudi, 630 004, Tamil Nadu, India.
  • Centre for Ocean Research, Sathyabama Institute of Science and Technology (Deemed to be University), Chennai, 600 119, Tamil Nadu, India. Electronic address: govindtu@gmail.com.

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India
  • Biomolecular Interaction Centre, University of Canterbury

Zitieren

APA

Panchalingam, S., Jayaraman, M., Jeyaraman, J., & Kasivelu, G. (2024). Harnessing marine natural products to inhibit PAD4 triple mutant: A structure-based virtual screening approach for rheumatoid arthritis therapy. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2024.110164

Vancouver

Panchalingam S, Jayaraman M, Jeyaraman J, Kasivelu G. Harnessing marine natural products to inhibit PAD4 triple mutant: A structure-based virtual screening approach for rheumatoid arthritis therapy. Archives of Biochemistry and Biophysics. 2024. doi:10.1016/j.abb.2024.110164

BibTeX
@article{Panchalingam2024,
  author = {Panchalingam, Santhiya and Jayaraman, Manikandan and Jeyaraman, Jeyakanthan and Kasivelu, Govindaraju},
  title = {Harnessing marine natural products to inhibit PAD4 triple mutant: A structure-based virtual screening approach for rheumatoid arthritis therapy},
  journal = {Archives of Biochemistry and Biophysics},
  year = {2024},
  doi = {10.1016/j.abb.2024.110164}
}
Kostenlos starten →